Antoxis is a pre-clinical drug discovery company that utilises its patented Kromex™ chemistry scaffold to generate New Chemical Entities (NCE) targeting a number of high-value clinical indications. This innovative Kromex™ scaffold is developed from an in-depth knowledge of free radical biology and redox chemistry and protects over 100 Million compounds. This Kromex™ NCE library contains molecules with potential to modulate a broad spectrum of oxidative stress associated diseases and conditions that involve mitochondrial dysfunction. Antoxis is currently focusing its efforts on a sub-set of Kromex™ compounds that show rapid mito-targeting (minutes), potent mito-activity (100 fold greater than competing agents) and long term stability within the cell (48 h).